Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$25.68
-0.33 (-1.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $170.3M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
22.9x
↑EV/EBITDA
11.5x
↓ROE
8.4%
↑Gross Margin
28.5%
↓Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.3%
FCF CAGR
—
FCF margin
13.9%
FCF / Net income
1.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.34B · net income $151.0M · FCF $186.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.34B | $1.34B | $1.30B | $1.16B | $1.11B |
| Net Income | $151.0M | $151.0M | $146.4M | $112.2M | $95.0M |
| EBITDA | $316.0M | $316.0M | $302.0M | $208.4M | $195.8M |
| EPS | 1.11 | 1.11 | 1.08 | 0.83 | 0.71 |
| Gross Margin | 28.5% | 28.5% | 28.3% | 27.4% | 27.3% |
| Operating Margin | 14.0% | 14.0% | 14.0% | 12.0% | 10.9% |
| Net Margin | 11.3% | 11.3% | 11.3% | 9.7% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.28 | 0.31 | 0.29 |
| Current Ratio | 1.39 | 1.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $186.1M | $186.1M | $170.3M | $47.2M | $-124.9M |
| Returns | |||||
| ROE | 8.4% | 8.4% | 8.6% | 7.1% | 6.4% |
| Valuation | |||||
| P/E | 22.93 | 22.93 | 22.14 | 31.52 | 32.83 |
| EV/EBITDA | 11.53 | 11.53 | 11.51 | 18.55 | 17.60 |
| P/B | 1.95 | 1.95 | 1.90 | 2.23 | 2.11 |
| Growth & Yield | |||||
| Revenue Growth | 3.0% | 3.0% | 12.2% | 4.0% | — |
| EPS Growth | 2.8% | 2.8% | 30.1% | 16.9% | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
27.1%
EPS terminal req.
$2.28
Spread vs growth
-24.3%
5Y implied EPS CAGR
20.0%
EPS terminal req.
$2.76
Spread vs growth
-17.2%
10Y implied EPS CAGR
14.9%
EPS terminal req.
$4.44
Spread vs growth
-12.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.4%
Start / end P/E
25.8x → 23.1x
EPS bridge
1.08 → 1.11
Residual
-0.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.